Zhongguo shi yan xue ye xue za zhi · 2025
[Efficacy and Safety of Polatuzumab Vedotin Combined with Chemotherapy in the Treatment of Relapsed and Refractory Diffuse Large B-Cell Lymphoma].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jin Ke-Ting, Xia Jin-Dan, Qian Chu-Yun, Zhang Qian, Jiang Qian, Chen Song-Di, Zhang Wei-Ze, Mao Lu-Ling, Zhao Yi
Аннотация
OBJECTIVE: To observe the efficacy and safety of polatuzumab vedotin (pola) combined with chemotherapy in the treatment of relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL).
METHODS: A total of 23 patients with R/R DLBCL treated at the First Affiliated Hospital of Zhejiang University and its Liangzhu Branch from April 2023 to March 2024 were retrospectively collected. All patients were treated with pola combined with chemotherapy regimens such as BR, R-GDP, R-CHOP, or other regimens.
RESULTS: All 23 patients were evaluable for efficacy, with 10 achieving complete response (CR), 7 partial response (PR), 3 stable disease (SD), and 3 progressive disease (PD). The most common adverse events included myelosuppression, fever, and pulmonary infection. No severe adverse events resulted in drug withdrawal.
CONCLUSION: Pola combined with chemotherapy demonstrates promising efficacy and a favorable safety profile in the treatment of R/R DLBCL.
METHODS: A total of 23 patients with R/R DLBCL treated at the First Affiliated Hospital of Zhejiang University and its Liangzhu Branch from April 2023 to March 2024 were retrospectively collected. All patients were treated with pola combined with chemotherapy regimens such as BR, R-GDP, R-CHOP, or other regimens.
RESULTS: All 23 patients were evaluable for efficacy, with 10 achieving complete response (CR), 7 partial response (PR), 3 stable disease (SD), and 3 progressive disease (PD). The most common adverse events included myelosuppression, fever, and pulmonary infection. No severe adverse events resulted in drug withdrawal.
CONCLUSION: Pola combined with chemotherapy demonstrates promising efficacy and a favorable safety profile in the treatment of R/R DLBCL.